Related Experiment Video
Updated: Jun 12, 2026
09:06
Localization of Plasma Membrane and Intracellular Neuronal Nicotinic Acetylcholine Receptors Using Quantitative Imaging in Mammalian Cells
Published on: December 19, 2025
Negative allosteric modulators that target human alpha4beta2 neuronal nicotinic receptors
Brandon J Henderson1, Ryan E Pavlovicz, Jerad D Allen
1Division of Pharmacology, College of Pharmacy, Ohio State University, Columbus, Ohio 43210, USA.
Summary
Negative allosteric modulators (NAMs) targeting neuronal nicotinic acetylcholine receptors (nAChRs) show therapeutic promise. Researchers identified KAB-18, a selective Hα4β2 nAChR antagonist, using structure-activity relationships and computational modeling.
Area of Science:
- Neuroscience
- Pharmacology
- Medicinal Chemistry
Background:
- Allosteric modulation of neuronal nicotinic acetylcholine receptors (nAChRs) is a key therapeutic strategy.
- Previous work identified compounds acting as negative allosteric modulators (NAMs) of nAChRs.
Purpose of the Study:
- To investigate the effects of 30 NAMs on human alpha4beta2 (Hα4β2) and human alpha3beta4 (Hα3β4) nAChRs.
- To identify selective modulators for specific nAChR subtypes.
Main Methods:
- Calcium accumulation assays to determine IC50 values for 30 NAMs.
- Structure-activity relationship (SAR) analysis.
- 3D-QSAR (CoMFA, CoMSIA) modeling and pharmacophore construction.
- Molecular docking and dynamics simulations on an Hα4β2 nAChR homology model.
- Mutagenesis studies.
Main Results:
- 30 NAMs inhibited nAChR activation with IC50 values from 2.4 µM to >100 µM.
- Several NAMs exhibited selectivity for Hα4β2 nAChRs in the low micromolar range.
- A lead molecule, KAB-18, was identified with relative selectivity for Hα4β2 nAChRs.
- SAR, computational models, and mutagenesis supported a binding mode for KAB-18 at the α/β subunit interface.
Conclusions:
- SAR, computational, and molecular biology approaches are crucial for designing potent and selective nAChR antagonists.
- KAB-18 represents a promising lead compound for targeting Hα4β2 nAChRs.
More Related Videos
Related Concept Videos
01:15Cholinergic Receptors: Nicotinic
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:28Drugs Acting on Autonomic Ganglia: Blockers
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...